From the Wires
Chugai and Debiopharm Group Announce an Exclusive License Agreement for Anti-Cancer Agent, FF284 (Debio 1347)
Jan. 8, 2013 01:00 AM
LAUSANNE, Switzerland and TOKYO, January 8, 2013 /PRNewswire/ --
Chugai Pharmaceutical Co., Ltd. ("Chugai") and Debiopharm GroupTM ("Debiopharm") announced today that on December 17, 2012, they entered into a licensing agreement regarding FF284 (called Debio 1347 by Debiopharm) discovered by Chugai and which is about to start clinical development in oncology.
Under this license agreement, Chugai will grant Debiopharm an exclusive license to develop and commercialise FF284 (Debio 1347) in all countries worldwide including Japan. Under the same agreement, Chugai will grant a non-exclusive license to develop and commercialise a companion diagnostic for FF284 (Debio 1347). According to the terms of the license, Debiopharm and Chugai will collaborate to conduct a Phase I dose escalation study. In return for the license, Chugai will receive an upfront fee, milestone and royalty payments from Debiopharm.
"We are delighted that we have concluded a license agreement for the development and marketing of FF284 with Debiopharm" said Tatsuro Kosaka, President and COO of Chugai. "We will continue to cooperate with Debiopharm in order to deliver FF284 to cancer patients as soon as possible."
"We are happy to combine forces with Chugai for the development of Debio 1347," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. "Due to its profile, Debio 1347 is expected to become a tailored treatment with high anti-tumour activity, which is very promising."
About Chugai
Chugai Pharmaceutical [Head Office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specialises in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai's research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and Ukima is conducting research for technology development for industrial production. Overseas, Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue of Chugai in 2011 totalled 373.5 billion yen and the operating income was 62.4 billion yen. They are aiming at a consolidated revenue of 418.5 billion yen and operating income of 80 billion yen for 2012.
Additional information is available on the Internet at http://www.chugai-pharm.co.jp/.
About Debiopharm
Debiopharm GroupTM (Debiopharm) is a Swiss-based global biopharmaceutical group of companies founded in 1979 with headquarters in Lausanne. Debiopharm has a focus on the development of innovative prescription drugs that target unmet medical needs. Oncology is the group's main area of expertise. Debiopharm in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine.
For more information about Debiopharm GroupTM: http://www.debiopharm.com.
Debiopharm S.A. Contact
Beatrice Hirt
Communication Coordinator
bhirt@debiopharm.com
Tel.: +41-21-321-0111
Chugai Pharmaceutical Co., Ltd.
Corporate Communications
Tel.: +81-(0)3-3273-0881
Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel.: +44-(0)20-7379-5151
bhudspith@maitland.co.uk
In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel.: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com
SOURCE The Debiopharm Group
About PR NewswireCopyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
.gif)
Hyper-V Replica is our included asynchronous site-to-site VM replication capability for Windows Server 2012 and our free Hyper-V Server 2012 bare-metal enterprise-grade hypervisor. Using Hyper-V Replica, you can quickly implement a cost-effective disaster recovery plan for your busine...
We must bring together the worlds of SOA, BPM, Cloud, REST, and HOA. The secret to getting all these architectural trends to work well together centers on how we deal with state information. We must first separate application state from resource state, and then subsequently take the co...
If the leadership in your organization is mature and has a good track record – rest assured that a risk-mitigated decision to dabble in the public cloud is a vote of confidence in your direction.
It's little more than innate human nature to strive to control the environment around us....
Knowing what Big Data is, is one; knowing what a Big Data strategy is two; knowing how to implement that Big Data strategy is even more difficult. At least, that is how a lot of organizations perceive it. It must be said, in large process-directed organizations, what most of the large ...
“The last time I checked, people do not change their social security numbers very often...”
While in constant debate over data encryption and ease of access, I encountered a train of thought that made my jaw drop. A tradeshow attendee suggested encrypting everything, but just use a we...
